A company working on a herpes vaccination said that a trial of the experimental drug has been proven to reduce the rate at which patients released the virus. Meaning that this potential vaccine has the likelihood of reducing the infections of others. The fifteen percent reduction in the release of the virus by patients receiving the vaccine showed much better in the study than those who received a placebo, who showed no reduction.
The vaccine, called HerpV, reduced the severity of the infection by thirty-four percent. HerpV is being developed as an “off the shelf” vaccine. It has been said that more data is expected in the first half of 2014, showing how patients fared after the booster shoot.